MARKET

AXGT

AXGT

Axovant Gene Therapies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.07
+0.19
+3.89%
Closed 18:55 12/09 EST
OPEN
4.900
PREV CLOSE
4.880
HIGH
5.16
LOW
4.840
VOLUME
113.61K
TURNOVER
--
52 WEEK HIGH
19.60
52 WEEK LOW
3.810
MARKET CAP
115.55M
P/E (TTM)
-1.1443
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AXGT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AXGT News

  • Axovant Gene Therapies (AXGT) Investor Presentation - Slideshow
  • Seeking Alpha - Article.14h ago
  • Axovant Announces Amendment to Credit Facility with Hercules Capital
  • GlobeNewswire.6d ago
  • Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag
  • Zacks.11/19 14:40
  • Axovant's AXO-AAV-GM1 an Orphan Drug in U.S. for GM1 gangliosidosis
  • seekingalpha.11/18 17:46

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About AXGT

Axovant Gene Therapies Ltd., formerly Axovant Sciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson’s disease.
More

Webull offers Axovant Gene Therapies Ltd (AXGT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.